The supplemental New Drug Application is supported by Phase III data, which showed Caplyta significantly prolonged time to ...

While the growing oncology pipeline offers tremendous potential, the path from clinical development through to commercial ...

Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, outlines how the company is ...

The National Alliance on Mental Illness (NAMI) issued a response to the bill, stating that the cuts to Medicare and Medicaid ...

Traditionally, COVID vaccines have been delivered via injections. According to the Cincinnati Children’s Hospital Medical ...

Financial planning and analysis (FP&A) is an important part of any business’ strategy. At the moment, FP&A in pharma is going through a complex period of change. While new technologies are making it ...

Does Novo Nordisk support compounded GLP-1s? However, companies like Novo Nordisk have raised concerns when it comes to compounding. For drugs as popular as GLP-1s, there is a risk that some ...

This Peer Exchange® starts off with an introduction of the panel: Edward Ahn, CEO of MEDIPOST, Inc.; Rob Philo, Founder and CEO of Core Market Access Advisors; and Shana Gunderson Hua, PharmD, Vice ...

First and only daily disposable lens for multifocal astigmatism: Acuvue Oasys Max 1-Day Multifocal for Astigmatism is the first lens designed to correct both presbyopia and astigmatism in a daily ...

In an interview with Pharmaceutical Executive, Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, discussed the company’s expanding efforts in solid tumors, a space where it is still ...

Disconnected tools create hidden costs The traditional approach to trial management relies on a mix of solutions, including eConsent platforms, electronic patient reported outcome systems (ePROs), ...